Gangrene future or investigational therapies

Gangrene Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gangrene from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gangrene future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gangrene future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gangrene future or investigational therapies
CDC on Gangrene future or investigational therapies
Gangrene future or investigational therapies in the news
Blogs on Gangrene future or investigational therapies
Directions to Hospitals Treating Gangrene
Risk calculators and risk factors for Gangrene future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.

Overview

A novel gene therapeutic approach is currently conducted to promote reperfusion and angiogenesis of ischemic tissues, which can help in limb salvage. Ongoing study on this approach is conducted on mice and it involves the intramuscular injection of adeno-associated virus/ (AAV) vector, and E-selectin.